istesso.co.uk
Open in
urlscan Pro
78.141.198.232
Public Scan
Submitted URL: http://istesso.co.uk/
Effective URL: https://istesso.co.uk/
Submission: On January 30 via api from US — Scanned from GB
Effective URL: https://istesso.co.uk/
Submission: On January 30 via api from US — Scanned from GB
Form analysis
0 forms found in the DOMText Content
* Home * About * Science * Pipeline * News & Press * Policies * Contact Your browser does not support the video tag. FINDING NATURE’S RHYTHM A NEW HORIZON FOR AUTOIMMUNITY. Istesso is at the forefront of an emerging field of science called immunometabolism. Our pioneering work has the potential to revolutionise the treatment of autoimmunity and, as a result, improve the lives of millions around the world. We develop novel treatments for unmet needs in autoimmunity. Our groundbreaking products work by reprogramming cellular metabolism and have applications in autoimmune conditions such as rheumatoid arthritis and multiple sclerosis, as well as cancer. Read More PIPELINE Our pipeline consists of drugs that reprogram metabolism in target immune cells, thereby offering novel treatments for autoimmune conditions. We are at the most exciting stage of development of our first-in-class pipeline… MBS2320 Rheumatoid arthritis Discovery Pre-clinical Phase 1 Phase 2 Phase 3 MBS2612 Autoimmune, neuroprotection/fibrosis Discovery Pre-clinical Phase 1 Phase 2 Phase 3 IST003 Autoimmune, neuroprotection/fibrosis Discovery Pre-clinical Phase 1 Phase 2 Phase 3 Read More "It’s hard to imagine anything more rewarding than translating exciting science into treatments with the potential to benefit patients." Lisa Patel Chief Executive Officer LATEST NEWS ISTESSO ANNOUNCES FDA FAST TRACK AND ORPHAN DRUG DESIGNATION FOR MBS2320 Istesso Limited, the immunometabolism drug discovery and development company, today... 5th December 2022 CEO LISA PATEL ON CAREERS IN DISCOVERY Our CEO Lisa Patel was recently featured on Tom Froggatt’s... 30th November 2022 MBS2320 ADMINISTERED TO PARTICIPANTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS Istesso Limited, the immunometabolism drug discovery and development company, today... 6th September 2022 More news * Linkedin * Twitter * Privacy Policy * Cookie Policy Site by Lolly Agency We are using cookies to give you the best experience on our website. You can find out more about which cookies we are using or switch them off in settings. Accept Reject Change cookie settings Close GDPR Cookie Settings * Privacy Overview * Strictly Necessary Cookies * 3rd Party Cookies * Cookie Policy Privacy Overview This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. More information about our Privacy Policy Strictly Necessary Cookies Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings. Enable or Disable Cookies If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again. 3rd Party Cookies This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website. Enable or Disable Cookies Please enable Strictly Necessary Cookies first so that we can save your preferences! Cookie Policy More information about our Cookie Policy Enable All Save Changes